Related references
Note: Only part of the references are listed.Systemic Therapy for Metastatic Renal-Cell Carcinoma
Toni K. Choueiri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Economic Evaluation of Nivolumab as a Second-Line Treatment for Advanced Renal Cell Carcinoma From US and Chinese Perspectives
Xiao Min Wan et al.
CANCER (2017)
Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: the largest multicenter retrospective analysis of survival and prognostic factors
Hai-Liang Zhang et al.
BMC CANCER (2017)
Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Management of sunitinib adverse events in renal cell carcinoma patients: The Asian experience
Aiping Zhou
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2012)
Sunitinib for Asian Patients with Advanced Renal Cell Carcinoma: A Comparable Efficacy with Different Toxicity Profiles
Hyo Song Kim et al.
ONCOLOGY (2011)
The Efficacy and Safety of Sunitinib in Korean Patients with Advanced Renal Cell Carcinoma: High Incidence of Toxicity Leads to Frequent Dose Reduction
Changhoon Yoo et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2010)
Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial
Martin E. Gore et al.
LANCET ONCOLOGY (2009)
Share Paper
